Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sernova Corp SEOVF


Primary Symbol: T.SVA

Healthcare Biotechnology
Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch... see more

Recent & Breaking News (TSX:SVA)

Sernova (TSXV:SVA) slated to release clinical trials amid share price surge

Brieanna McCutcheon  January 11, 2021

Sernova to Present at H.C. Wainwright BioConnect 2021 Conference

TheNewsWire December 18, 2020

(PODCAST) Sernova's Visibility Increases Ahead of Holidays

TheNewsWire December 16, 2020

Sernova Corp. Responds to Market Activity

TheNewsWire December 11, 2020

Sernova Medical Advances Gain Media Attention

TheNewsWire December 3, 2020

Sernova Announces Clinical Trial Investigator Presentation at the ASTS 21st Winter Symposium

TheNewsWire November 30, 2020

Sernova Provides Clinical Update on U.S. Phase I/II Cell Pouch(TM) Trial for Type 1 Diabetes

TheNewsWire November 18, 2020

Sernova Announces 3-Month Extension of Warrants

TheNewsWire October 30, 2020

(Exclusive) Sernova Presents at TSX Life Sciences Investor Day: Available Now!

TheNewsWire October 29, 2020

Sernova to Present at TSX Life Sciences Investor Day

TheNewsWire October 27, 2020

Sernova to Present at Virtual BIO Investor Forum

TheNewsWire September 24, 2020

Sernova Closes Oversubscribed Private Placement and Accelerates Development Programs

TheNewsWire September 23, 2020

Sernova to Participate in Cell and Gene Therapies for Chronic Conditions Panel at the Virtual 2020 Cell & Gene Meeting on the Mesa Conference

TheNewsWire September 10, 2020

Sernova Announces Up to $3 Million Private Placement Financing with a Lead Order of $2 Million

TheNewsWire September 9, 2020

Sernova Enters into Exclusive Worldwide License Agreement with University of Miami for Therapeutic Cell Immune Protection Technologies

TheNewsWire August 4, 2020

Dr. Anke M. Schulte Joins Sernova Global Advisory Board

TheNewsWire July 16, 2020

Sernova Highlights Positive Results Presented at the American Diabetes Association's Virtual 80th Scientific Sessions

TheNewsWire June 18, 2020

Sernova Completes Acquisition of Cellular Local Immune Protection Technology

TheNewsWire June 15, 2020

Sernova to Acquire Cellular Local Immune Protection Technology Accelerating Expansion of its Regenerative Medicine Therapeutics Platform

TheNewsWire June 8, 2020

Sernova to Present Clinical Validation of the Cell Pouch as a Viable, Safe Site for Diabetes Cell Therapy at the American Diabetes Association's Virtual 80th Scientific Sessions

TheNewsWire June 3, 2020